PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate the cost-effectiveness of sotorasib versus docetaxel in non-small cell lung cancer (NSCLC) patients with KRASG12C mutation from the China and United States\'social perspective.
UNASSIGNED: A Markov model that included three states (progression-free survival, post-progression survival, and death) was developed. Incremental cost-effectiveness ratio (ICER), quality-adjusted life-year (QALY), and incremental QALY were calculated for the two treatment strategies. One-way sensitivity analysis was used to investigate the factors that had a greater impact on the model results, and tornado diagrams were used to present the results. Probabilistic sensitivity analysis was performed with 1,000 Monte Carlo simulations. Assume distributions based on parameter types and randomly sample all parameter distributions each time., The results were presented as cost-effectiveness acceptable curves.
UNASSIGNED: This economic evaluation of data from the CodeBreak 200 randomized clinical trial. In China, sotorasib generated 0.44 QAYL with a total cost of $84372.59. Compared with docetaxel, the ICER value of sotorasib was $102701.84/QALY, which was higher than willingness to pay (WTP), so sotorasib had no economic advantage. In the US, sotorasib obtained 0.35 QALY more than docetaxel, ICER was $15,976.50/QALY, which was more than 1 WTP but less than 3 WTP, indicating that the increased cost of sotorasib was acceptable. One-way sensitivity analysis showed that the probability of sotorasib having economic benefits gradually increased when the cost of follow-up examination was reduced in China. And there was no influence on the conclusions within the range of changes in China. When the willingness to pay (WTP) exceeds $102,500, the probability of sotorasib having cost effect increases from 0% to 49%.
UNASSIGNED: Sotorasib had a cost effect from the perspective in the United States. However, sotorasib had no cost effect from the perspective in China, and only when the WTP exceeds $102,500, the probability of sotorasib having cost effect increases from 0% to 49%.
UNASSIGNED: A Markov model that included three states (progression-free survival, post-progression survival, and death) was developed. Incremental cost-effectiveness ratio (ICER), quality-adjusted life-year (QALY), and incremental QALY were calculated for the two treatment strategies. One-way sensitivity analysis was used to investigate the factors that had a greater impact on the model results, and tornado diagrams were used to present the results. Probabilistic sensitivity analysis was performed with 1,000 Monte Carlo simulations. Assume distributions based on parameter types and randomly sample all parameter distributions each time., The results were presented as cost-effectiveness acceptable curves.
UNASSIGNED: This economic evaluation of data from the CodeBreak 200 randomized clinical trial. In China, sotorasib generated 0.44 QAYL with a total cost of $84372.59. Compared with docetaxel, the ICER value of sotorasib was $102701.84/QALY, which was higher than willingness to pay (WTP), so sotorasib had no economic advantage. In the US, sotorasib obtained 0.35 QALY more than docetaxel, ICER was $15,976.50/QALY, which was more than 1 WTP but less than 3 WTP, indicating that the increased cost of sotorasib was acceptable. One-way sensitivity analysis showed that the probability of sotorasib having economic benefits gradually increased when the cost of follow-up examination was reduced in China. And there was no influence on the conclusions within the range of changes in China. When the willingness to pay (WTP) exceeds $102,500, the probability of sotorasib having cost effect increases from 0% to 49%.
UNASSIGNED: Sotorasib had a cost effect from the perspective in the United States. However, sotorasib had no cost effect from the perspective in China, and only when the WTP exceeds $102,500, the probability of sotorasib having cost effect increases from 0% to 49%.
摘要：
■从中国和美国的社会角度评估索托拉西布与多西他赛在非小细胞肺癌（NSCLC）KRASG12C突变患者中的成本-效果。
■马尔可夫模型，包括三个状态（无进展生存期，进展后生存,和死亡）被开发。增量成本效益比(ICER)，质量调整寿命年(QALY)，并计算了两种治疗策略的增量QALY。单因素敏感性分析用于考察对模型结果影响较大的因素,和龙卷风图被用来展示结果。使用1,000个蒙特卡罗模拟进行了概率敏感性分析。假设分布基于参数类型，并且每次随机采样所有参数分布。,结果呈现为成本效益可接受曲线。
■这是对CodeBreak200随机临床试验数据的经济评估。在中国,sotorasib产生了0.44QAYL，总成本为84372.59美元。与多西他赛相比,索托拉斯的ICER值为102701.84美元/QALY，高于支付意愿(WTP)，所以索托拉西没有经济优势。在美国,索托拉西比多西他赛获得0.35QALY，ICER为$15,976.50/QALY，大于1WTP但小于3WTP，表明索托拉西布的成本增加是可以接受的。单因素敏感性分析显示,随着我国后续检查费用的降低,索托拉西具有经济效益的概率逐渐增加。在中国的变化范围内，对结论没有影响。当支付意愿（WTP）超过102,500美元时，索托拉斯具有成本效应的概率从0%增加到49%。
■从美国的角度来看，Sotorasib具有成本效应。然而,从中国的角度来看，索托拉西没有成本效应，只有当WTP超过$102,500时，sotorasib具有成本效应的概率从0%增加到49%。
■马尔可夫模型，包括三个状态（无进展生存期，进展后生存,和死亡）被开发。增量成本效益比(ICER)，质量调整寿命年(QALY)，并计算了两种治疗策略的增量QALY。单因素敏感性分析用于考察对模型结果影响较大的因素,和龙卷风图被用来展示结果。使用1,000个蒙特卡罗模拟进行了概率敏感性分析。假设分布基于参数类型，并且每次随机采样所有参数分布。,结果呈现为成本效益可接受曲线。
■这是对CodeBreak200随机临床试验数据的经济评估。在中国,sotorasib产生了0.44QAYL，总成本为84372.59美元。与多西他赛相比,索托拉斯的ICER值为102701.84美元/QALY，高于支付意愿(WTP)，所以索托拉西没有经济优势。在美国,索托拉西比多西他赛获得0.35QALY，ICER为$15,976.50/QALY，大于1WTP但小于3WTP，表明索托拉西布的成本增加是可以接受的。单因素敏感性分析显示,随着我国后续检查费用的降低,索托拉西具有经济效益的概率逐渐增加。在中国的变化范围内，对结论没有影响。当支付意愿（WTP）超过102,500美元时，索托拉斯具有成本效应的概率从0%增加到49%。
■从美国的角度来看，Sotorasib具有成本效应。然而,从中国的角度来看，索托拉西没有成本效应，只有当WTP超过$102,500时，sotorasib具有成本效应的概率从0%增加到49%。
